Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (38)

2024

  1. An atlas of cells in the human tonsil

    Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  4. Natural Hydrogels Support Kidney Organoid Generation and Promote In Vitro Angiogenesis

    Advanced Materials, Vol. 36, Núm. 34

  5. PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma

    Leukemia

2023

  1. Epigenome profiling reveals aberrant DNA methylation signature in GATA2 deficiency

    Haematologica, Vol. 108, Núm. 9, pp. 2551-2557

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

2022

  1. CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

    Science Advances, Vol. 8, Núm. 39

  2. Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma

    Leukemia, Vol. 36, Núm. 2, pp. 583-587

  3. Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts

    American Journal of Hematology

  4. Risk Factors of DAIR Failure and Validation of the KLIC Score: A Multicenter Study of Four Hundred Fifty-Five Patients

    Surgical Infections, Vol. 23, Núm. 3, pp. 280-287

2021

  1. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  2. Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation

    Nature Communications, Vol. 12, Núm. 1

  3. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma

    Leukemia, Vol. 35, Núm. 10, pp. 3012-3016

  4. Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

    Nature Communications, Vol. 12, Núm. 1

2020

  1. Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma

    Genome Research, Vol. 30, Núm. 9, pp. 1217-1227

  2. The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

    Nature Cancer, Vol. 1, Núm. 11, pp. 1066-1081

2019

  1. Engineered Macroscale Cardiac Constructs Elicit Human Myocardial Tissue-like Functionality

    Stem Cell Reports, Vol. 13, Núm. 1, pp. 207-220

  2. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

    Haematologica, Vol. 104, Núm. 8, pp. 1572-1579